Navigation Links
Barrow scientist leads insula research
Date:7/7/2010

(PHOENIX, AZ) -- A scientist at Barrow Neurological Institute is leading the global discussion and research on a hidden lobe of the brain called the insula. A.D. "Bud" Craig, PhD, who began studying the often-ignored lobe more than two decades ago, has organized and edited a special edition of the journal Brain Structure and Function dedicated to the emerging medical and scientific interest in the insula.

This special edition contains 21 articles describing the latest research and insights from scientists and clinicians from around the world who recognize the insula as the key to their own field of interest and perhaps human consciousness.

The insula is a prune-sized area located deep within the brain. It was long ignored because scientists could not probe the area with surface electrodes. With the invention of sophisticated brain imaging techniques such as functional magnetic resonance imaging (fMRI) activation of the region has been observed in a surprisingly wide range of studies.

"Rapidly accumulating evidence indicates that this area of the brain is uniquely involved in virtually every human emotion and behavior," says Dr. Craig. "Similarly, clinical evidence indicates that it is crucially involved in a variety of syndromes, including addiction, anxiety, depression, anosognosia, schizophrenia and frontotemporal dementia."

Dr. Craig says that the overall goal of the special issue on the insula in Brain Structure and Function is to provide a solid starting point for new investigators by identifying the issues and opportunities for advances in the knowledge of this unique portion of the human brain.

An "intense" discussion about the role of the insula is urgently needed, says Dr. Craig, because many researchers have not had knowledge of its role and so little had been written about it.

"The insula is finally emerging from its hiding place inside the human brain," says Dr. Craig. "Its central importance to all human feelings and behaviors makes it an extraordinarily important target for potential treatments of many mental dysfunctions, using drugs or sophisticated biofeedback methods."


'/>"/>

Contact: Lynne Reaves
lynne.reaves@chw.edu
602-406-4734
St. Joseph's Hospital and Medical Center
Source:Eurekalert

Related biology news :

1. Barrow scientist receives $450K MDA grant
2. New era of pain drugs advanced by Barrow researcher
3. Barrow researcher finds natural hydrogel helps heal spinal cord
4. Barrow scientist awarded $400,000 grant to study cell associated with intuition and autism
5. Barrow scientists solve 200-year-old scientific debate involving visual illusions
6. Marine scientists return with rare creatures from the deep
7. Scientists find direct line from development to growth
8. UM School of Medicine scientists develop new strategy that may improve cognition
9. Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria
10. NOAA-supported scientists predict larger than average Gulf dead zone
11. SAGE to publish the Bulletin of the Atomic Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: